Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus

Diabetes Technology and Therapeutics

Volumn 15, Issue 10, 2013, Pages 859-869

  Huang, Zhimin ^a   Wan, Xuesi ^a   Liu, Juan ^a   Deng, Wanping ^a   Chen, Ailing ^a   Liu, Liehua ^a   Liu, Jianbin ^a   Wei, Guohong ^a   Li, Hai ^a   Fang, Donghong ^a   Li, Yanbing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; INSULIN ASPART; INSULIN LISPRO; INTRAMYOCELLULAR LIPID; LIPID; MALONALDEHYDE; METFORMIN; ROSIGLITAZONE; THIOCTIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOMEOSTASIS MODEL ASSESSMENT INDEX; HUMAN; HYPOGLYCEMIA; INSULIN PUMP; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIOXIDANTS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN-SECRETING CELLS; LIPIDS; MALE; MALONDIALDEHYDE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; THIOCTIC ACID; TIME FACTORS;

EID: 84884561374     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2013.0013     Document Type: Article

References (37)

1. Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-1356. (Pubitemid 27366805)
2. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of b-cell function. Diabetes Care 2004;27:2597-2602. (Pubitemid 39441457)
3. Weng J, Li Y, Xu W, Shi L, Zhang Q, ZhuD,Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H: Effect of intensive insulin therapy on b-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760. (Pubitemid 351697950)
4. Park S, Choi SB: Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003;19:124-130. (Pubitemid 36417196)
5. Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-1032. (Pubitemid 38579760)
6. Davidson MB: Pro's and con's of the early use of insulin in the management of type 2 diabetes: A clinical evaluation. Curr Opin Endocrinol Diabetes Obes 2009;16:107-112.
7. Chen A, Huang Z, Wan X, Deng W, Wu J, Li L, Cai Q, Xiao H, Li Y: Attitudes toward diabetes affects maintenance of drug-free remission in patients with newly diagnosed type 2 diabetes mellitus after short-term continuous subcutaneous insulin infusion treatment. Diabetes Care 2012;35:474-481.
8. Chavez JA, Summers SA: Lipid oversupply, selective insulin resistance, and lipotoxicity: molecular mechanisms. Biochim Biophys Acta 2010;1801:252-265.
9. Henriksen EJ: Exercise training and the antioxidant a-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Biol Med 2006;40:3-12. (Pubitemid 41759398)
10. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443. (Pubitemid 44903747)
11. Boden G, Zhang M: Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006;15:243-250. (Pubitemid 43338145)
12. Vasudevan AR, Balasubramanyam A: Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. Diabetes Technol Ther 2004;6:850-863. (Pubitemid 40129333)
13. Lee BW, Kwon SJ, Chae HY, Kang JG, Kim CS, Lee SJ, Yoo HJ, Kim JH, Park KS, Ihm SH: Dose-related cytoprotective effect of alpha-lipoic acid on hydrogen peroxide-induced oxidative stress to pancreatic beta cells. Free Radic Res 2009;43:68-77.
14. Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; QUARTET Study Group: A long term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel group comparison trial. Diabet Med 2005;22:399-405. (Pubitemid 40516237)
15. Miller RA, Birnbaum MJ: An energetic tale of AMPKindependent effects of metformin. J Clin Invest 2010;120: 2267-2270.
16. Del Prato S, Marchetti P: Beta-and alpha-cell dysfunction in type 2 diabetes. Horm Metab Res 2004;36:775-781. (Pubitemid 40115899)
17. Berrish TS, Hetherington CS, Alberti KG, Walker M: Peripheral and hepatic insulin sensitivity in subjects with impaired glucose tolerance. Diabetologia 1995;38:699-704.
18. Evans JM, Ogston SA, Emslie-Smith MA, Morris A: Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulphonylureas and metformin. Diabetologia 2006;49:930-936.
19. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002;25:2244-2248. (Pubitemid 41071035)
20. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, Feldman L, Vassy J, Wilson R, Bass EB, Brancati FL: Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008;168:2070-2080.
21. Anfossi G, Russo I, Bonomo K, Trovati M: The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8:327-337.
22. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J: Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002;24:378-396. (Pubitemid 34275860)
23. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ: Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-1749. (Pubitemid 37254857)
24. Chiquette E, Ramirez G, Defronzo R: A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-2104. (Pubitemid 39419498)
25. Tiikkainen M, Hakkinen A-M, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004;53: 2169-2176. (Pubitemid 38970772)
26. van der Graaf M, Tack CJ, de Haan JH, Klomp DW, Heerschap A: Magnetic resonance spectroscopy shows an inverse correlation between intramyocellular lipid content in human calf muscle and local glycogen synthesis rate. NMR Biomed 2010;23:133-141.
27. Salgin B, Sleigh AJ, Williams RM, Jackson SJ, Bluck LJ, Murgatroyd PR, Humphreys SM, Harding S, Carpenter TA, Dunger DB: Intramyocellular lipid levels are associated with peripheral, but not hepatic, insulin sensitivity in normal healthy subjects. Clin Sci 2009;117:111-118.
28. van Loon LJ, Koopman R,Manders R, van derWeegenW, van Kranenburg GP, Keizer HA: Intramyocellular lipid content in type 2 diabetes patients compared with overweight sedentary men and highly trained endurance athletes. Am J Physiol Endocrinol Metab 2004;287:E558-E665.
29. Boden G, Homko C, Mozzoli M, Showel LC, Nichols C, Cheung P: Thiazolidinediones up regulate fatty acid uptake and oxidation in adipose tissue in diabetic patients. Diabetes 2005;54:880-885. (Pubitemid 40322094)
30. Boden G, Cheung P, Mozzoli M, Fried SK: Effect of thiazolidinediones on glucose and fatty acid metabolism in patients with type 2 diabetes. Metabolism 2003;52:753-759. (Pubitemid 36896311)
31. Bourron O, Daval M, Hainault I, Hajduch E, Servant JM, Gautier JF, Ferré P, Foufelle F: Biguanides and thiazolidine-diones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase. Diabetologia 2010;53:768-778.
32. Teranishi T, Ohara T, Maeda K, Zenibayashi M, Kouyama K, Hirota Y, Kawamitsu H, Fujii M, Sugimura K, Kasuga M: Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007;56:1418-1424. (Pubitemid 47404606)
33. Tamura Y, Watada H, Sato F, Kumashiro N, Sakurai Y, Hirose T, Tanaka Y, Kawamori R: Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. Diabetes Obes Metab 2008;10:733-738.
34. Malin SK, Gerber R, Chipkin SR, Braun B: Independent and combined effects of exercise training and metformin on insulin sensitivity in individuals with prediabetes. Diabetes Care 2012;35:131-136.
35. Xiao CT, Giacca A, Lewis GF: Short-term oral a-lipoic acid does not prevent lipid-induced dysregulation of glucose homeostasis in obese and overweight nondiabetic men. Am J Physiol Endocrinol Metab 2011;301:E736-E741.
36. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, Augustin HJ, Dietze GJ, Rett K: Oral administration of RAC-alpha lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309-314. (Pubitemid 29395422)
37. Zhang WJ, Wei H, Hagen T, Frei B: Alpha-lipoic acid attenuates LPS-induced inflammatory responses by activating the phosphoinositide 3-kinase/Akt signaling pathway. Proc Natl Acad Sci USA 2007;104:4077-4082. (Pubitemid 47181581)